Comparison of Tenofovir Plus Lamivudine Versus Tenofovir Monotherapy in Patients with Lamivudine-resistant Chronic Hepatitis B

Chan Ho Park,Seok-Won Jung,Jung Woo Shin,Mi Ae Bae,Yoon Im Lee,Yong Tae Park,Hwa Sik Chung,Neung Hwa Park

Comparison of Tenofovir Plus Lamivudine Versus Tenofovir Monotherapy in Patients with Lamivudine-resistant Chronic Hepatitis B

2016

Chan Ho Park
Seok-Won Jung
Jung Woo Shin
Mi Ae Bae
Yoon Im Lee
Yong Tae Park
Hwa Sik Chung
Neung Hwa Park

Background/Aims: Tenofovir disoproxil fumarate (TDF) exhibits similar antiviral efficacy against treatment-naive and lamivudine (LAM)-resistant chronic hepatitis B (CHB). However, there are few clinical reports on the antiviral effects of TDF–LAM combination therapy compared to TDF monotherapy in patients with LAM-resistant CHB.

Keywords:

Hepatitis B
Tenofovir
Virology
Lamivudine
Hepatitis B virus
Liver function tests
Combination therapy
Medicine
Renal function
Gastroenterology
chronic hepatitis
Polymerase chain reaction
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations